CP101, an investigational microbiome therapeutic, restored microbiome diversity and prompted a sustained clinical cure among patients with recurrent Clostridioides difficile infection, according to a presentation at this year’s ACG in Las Vegas. “(The c. dif) therapies lead to significant microbiome disruptions which impairs colonization resistance,” Jessica R. Allegretti, MD, MPH, FACG, the director of fecal
In PRISM3, a multicenter, randomized, double-blind, placebo-controlled phase 2 trial, researchers assessed an investigational oral microbiome drug CP101 in 206 patients with recurrent C. difficle at 51 sites across the United States and Canada. The drug did meet the primary endpoint of sustained clinical cure among 74.5% of the patients with recurrent C. difficile who received a
Patients with both Clostridiodes difficile infection and inflammatory bowel disease showed improvement after fecal microbiota transplantation, Jessica Allegretti, MD, director of the FMT program at Brigham and Women’s Hospital, said during a presentation at Digestive Disease Week. The ICON study took place at four sites across the US. Results for FMT in C. dif alone
FMT (or “stool transplant”) reduced hospital stays and hospital costs for patients with recurrent C. difficile infection
Almost 1 in 5 patients with symptomatic inflammatory bowel disease also had non-Clostridium difficile enteric infection, according to a study published in The American Journal of Gastroenterology. Although the infections had an effect on treatment, there was no long-term effect. See the article on MedPage Today here.
An article appearing in Nature suggested that a common food additive known as trehalose might be responsible for the current Clostridium difficile epidemic. The Nature paper shows us that two of the most virulent strains of C. diff, including the “hypervirulent” ribotype 027, can metabolize even trace amounts of trehalose. They go on to show that when strains are mixed together, low
A study presented at the World Congress of Gastroenterology found patients with Clostridium difficile who received opioids during their hospital stay had higher rates of complicated infection and in-hospital mortality and longer length of average hospital stay, compared with patients in the control group. The findings were based on medical records of 302 patients hospitalized
C. difficile infection rates climbed annually from 2000 to 2010, and in 2011 caused almost 500,000 illnesses and killed about 29,000 people in the US according to the CDC. However, preliminary analysis of data from the CDC’s Emerging Infections Program showed that the rate of new Clostridium difficile infections in hospitals and nursing homes nationwide
